Drugs / Yulinzhu
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07550998 | Apr 2026 → Oct 2027 expected | ovarian dysfunction | The University of Hong Kong | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yulinzhu | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07550998 ↗ |
| Known as | 毓麟珠 | “Yulinzhu (毓麟珠) originally published in The Complete Compendium of \[Zhang\] Jingyue (景岳全書), the mechanisms of action are nourishing kidney essence, qi and blood” NCT07550998 ↗ |